<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35313532</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-9368</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Metabolism open</Title><ISOAbbreviation>Metabol Open</ISOAbbreviation></Journal><ArticleTitle>Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges.</ArticleTitle><Pagination><StartPage>100180</StartPage><MedlinePgn>100180</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100180</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.metop.2022.100180</ELocationID><Abstract><AbstractText>Vaccination programs against SARS-CoV-2 constitute the mainstay of public health interventions against the global COVID-19 pandemic. Currently available vaccines have shown 90% or better rates of protection against severe disease and mortality. Barely a year after vaccines became available, the Omicron variant and its unprecedented speed of transmission has posed a new challenge. Overall, Omicron presents increased immune escape, transmissibility, and decreased pathogenicity. Vaccines do not offer a full protection against SARS-CoV-2 acquisition, since "breakthrough" infections may occur in fully vaccinated individuals, who may in turn spread the virus to others. Breakthrough infections may be causally related to the viral profile (viral variant and load, incubation period, transmissibility, pathogenicity, immune evasion), immunity characteristics (mucosal versus systemic immunity, duration of immunity, etc.), host determinants (age, comorbidities, immune status, immunosuppressive drugs) and vaccination properties (platform, antigen dose, dose number, dose interval, route of administration). Determining the rate of breakthrough infections may be challenging and necessitates the conduction of population-based studies regarding vaccine effectiveness as well as neutralizing antibody testing, a surrogate of immune protection. In this review, we analyze the causes of breakthrough infections, their clinical consequences (severity of infection and transmission), methods of determining their incidence as well as challenges and perspectives. Long COVID as well as multi-inflammatory syndrome in adolescents may be significantly reduced in breakthrough infections. The need for universal pancoranavirus vaccines that would aim at protecting against a plethora of SARS-CoV-2 variants as well as emerging variants is discussed. Finally, novel vaccine strategies, such as nasal vaccines, may confer robust mucosal and systemic protection, reducing efficiently transmission.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amanatidou</LastName><ForeName>Evropi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Biomathematics, School of Medicine, University of Thessaly, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gkiouliava</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Biomathematics, School of Medicine, University of Thessaly, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pella</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Biomathematics, School of Medicine, University of Thessaly, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serafidi</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Biomathematics, School of Medicine, University of Thessaly, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsilingiris</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>First Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vallianou</LastName><ForeName>Natalia G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>First Department of Internal Medicine, Evangelismos General Hospital, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karampela</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Second Department of Critical Care, Attikon General University Hospital, Medical School, National and Kapodistrian University of Athens, Chaidari, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalamaga</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biological Chemistry, School of Medicine, National and Kapodistrian University of Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Metabol Open</MedlineTA><NlmUniqueID>101767753</NlmUniqueID><ISSNLinking>2589-9368</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibody</Keyword><Keyword MajorTopicYN="N">Breakthrough infection</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Immunity</Keyword><Keyword MajorTopicYN="N">Neutralizing antibody</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">Pancoronavirus</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword><Keyword MajorTopicYN="N">Variant</Keyword><Keyword MajorTopicYN="N">Variant of concern</Keyword></KeywordList><CoiStatement>No conflict of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>22</Day><Hour>5</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35313532</ArticleId><ArticleId IdType="pmc">PMC8928742</ArticleId><ArticleId IdType="doi">10.1016/j.metop.2022.100180</ArticleId><ArticleId IdType="pii">S2589-9368(22)00018-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dalamaga M., Karampela I., Mantzoros C.S. Commentary: phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Metab, Clin Exp. 2020;109:154282. doi: 10.1016/j.metabol.2020.154282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2020.154282</ArticleId><ArticleId IdType="pmc">PMC7263254</ArticleId><ArticleId IdType="pubmed">32497535</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampela I., Vallianou N.G., Tsilingiris D., Christodoulatos G.S., Muscogiuri G., Barrea L., et al. Panminerva medica; 2021. Could inhaled corticosteroids be the game changers in the prevention of severe COVID-19? A review of current evidence.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/s0031-0808.21.04595-x</ArticleId><ArticleId IdType="pubmed">34859641</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallianou N.G., Tsilingiris D., Christodoulatos G.S., Karampela I., Dalamaga M. Anti-viral treatment for SARS-CoV-2 infection: a race against time amidst the ongoing pandemic. Metabolism open. 2021;10:100096. doi: 10.1016/j.metop.2021.100096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2021.100096</ArticleId><ArticleId IdType="pmc">PMC8143911</ArticleId><ArticleId IdType="pubmed">34056571</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N., Dagan N., Ben-Shlomo Y., Kepten E., Waxman J., Ohana R., et al. Safety of the BNT162b2 mRNA covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385:1078&#x2013;1090. doi: 10.1056/NEJMoa2110475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110475</ArticleId><ArticleId IdType="pmc">PMC8427535</ArticleId><ArticleId IdType="pubmed">34432976</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsilingiris D., Vallianou N.G., Karampela I., Liu J., Dalamaga M. Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2. Metabolism open. 2022;13:100159. doi: 10.1016/j.metop.2021.100159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2021.100159</ArticleId><ArticleId IdType="pmc">PMC8677426</ArticleId><ArticleId IdType="pubmed">34938983</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsilingiris D., Vallianou N.G., Karampela I., Dalamaga M. Vaccine induced thrombotic thrombocytopenia: the shady chapter of a success story. Metabolism open. 2021;11:100101. doi: 10.1016/j.metop.2021.100101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2021.100101</ArticleId><ArticleId IdType="pmc">PMC8217988</ArticleId><ArticleId IdType="pubmed">34179744</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallianou N.G., Tsilingiris D., Karampela I., Liu J., Dalamaga M. Herpes zoster following COVID-19 vaccination in an immunocompetent and vaccinated for herpes zoster adult: a two-vaccine related event? Metabolism open. 2022;13:100171. doi: 10.1016/j.metop.2022.100171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2022.100171</ArticleId><ArticleId IdType="pmc">PMC8830150</ArticleId><ArticleId IdType="pubmed">35169692</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie K.M., Li H., Bedinger D., Schendel S.L., Dennison S.M., Li K., et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study. Science. 2021;374:472&#x2013;478. doi: 10.1126/science.abh2315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh2315</ArticleId><ArticleId IdType="pmc">PMC9302186</ArticleId><ArticleId IdType="pubmed">34554826</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambrou A.S., Shirk P., Steele M.K., Paul P., Paden C.R., Cadwell B., et al. Genomic surveillance for SARS-CoV-2 variants: predominance of the Delta (B. 1.617. 2) and omicron (B. 1.1. 529) variants&#x2014;United States, June 2021&#x2013;January 2022. MMWR (Morb Mortal Wkly Rep) 2022;71:206. doi: 10.15585/mmwr.mm7106a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7106a4</ArticleId><ArticleId IdType="pmc">PMC8830620</ArticleId><ArticleId IdType="pubmed">35143464</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers B.L., Chakraborty S., Xue Y., Gelbart T., Gonzalez J.C., Cassidy A.G., et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci Transl Med. 2022;14 doi: 10.1126/scitranslmed.abn7842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn7842</ArticleId><ArticleId IdType="pmc">PMC8891085</ArticleId><ArticleId IdType="pubmed">35025672</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M., Czudnochowski N., Rosen L.E., Zepeda S.K., Bowen J.E., Walls A.C., et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science. 2022;375:864&#x2013;868. doi: 10.1126/science.abn8652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn8652</ArticleId><ArticleId IdType="pmc">PMC9427005</ArticleId><ArticleId IdType="pubmed">35076256</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiecco G., Storti S., Degli Antoni M., Foc&#xe0; E., Castelli F., Quiros-Roldan E. Omicron genetic and clinical peculiarities that may overturn SARS-CoV-2 pandemic: a literature review. Int J Mol Sci. 2022;23 doi: 10.3390/ijms23041987.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23041987</ArticleId><ArticleId IdType="pmc">PMC8876558</ArticleId><ArticleId IdType="pubmed">35216104</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency . UK Health Security Agency; 2022. COVID-19 vaccine surveillance report.https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1054071/vaccine-surveillance-report-week-6.pdf</Citation></Reference><Reference><Citation>Qassim S.H., Chemaitelly H., Ayoub H.H., AlMukdad S., Tang P., Hasan M.R., et al. Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 Omicron infections. medRxiv. 2022 doi: 10.1101/2022.03.02.22271771. 2022.03.02.22271771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.02.22271771</ArticleId><ArticleId IdType="pmc">PMC9213851</ArticleId><ArticleId IdType="pubmed">35639932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M., Krammer F., Regev-Yochay G., Lustig Y., Balicer R.D. SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. Nat Rev Immunol. 2022;22:57&#x2013;65. doi: 10.1038/s41577-021-00662-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00662-4</ArticleId><ArticleId IdType="pmc">PMC8649989</ArticleId><ArticleId IdType="pubmed">34876702</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Saunders N., Maes P., Guivel-Benhassine F., Planchais C., Buchrieser J., et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671&#x2013;675. doi: 10.1038/s41586-021-04389-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04389-z</ArticleId><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Bruel T., Grzelak L., Guivel-Benhassine F., Staropoli I., Porrot F., et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021;27:917&#x2013;924. doi: 10.1038/s41591-021-01318-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01318-5</ArticleId><ArticleId IdType="pubmed">33772244</ArticleId></ArticleIdList></Reference><Reference><Citation>Edara V.V., Manning K.E., Ellis M., Lai L., Moore K.M., Foster S.L., et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant. Cell Rep. Med. 2022;3:100529. doi: 10.1016/j.xcrm.2022.100529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100529</ArticleId><ArticleId IdType="pmc">PMC8784612</ArticleId><ArticleId IdType="pubmed">35233550</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K., Werner A.P., Koch M., Choi A., Narayanan E., Stewart-Jones G.B.E., et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med. 2021;384:1468&#x2013;1470. doi: 10.1056/NEJMc2102179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2102179</ArticleId><ArticleId IdType="pmc">PMC8008744</ArticleId><ArticleId IdType="pubmed">33730471</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameroni E., Saliba C., Bowen J.E., Rosen L.E., Culap K., Pinto D., et al. 2021. Broadly Neutralizing Antibodies Overcome SARS-CoV-2 Omicron Antigenic Shift. bioRxiv : the preprint server for biology.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.12.472269</ArticleId><ArticleId IdType="pmc">PMC9531318</ArticleId><ArticleId IdType="pubmed">35016195</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W., Shaw R.H., Supasa P., Liu C., Stuart A.S., Pollard A.J., et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet. 2022;399:234&#x2013;236. doi: 10.1016/s0140-6736(21)02844-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)02844-0</ArticleId><ArticleId IdType="pmc">PMC8687667</ArticleId><ArticleId IdType="pubmed">34942101</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S., Jackson L., Khoury D.S., Khan K., Moyo-Gwete T., Tegally H., et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv. 2021 doi: 10.1101/2021.12.08.21267417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.12.08.21267417</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen P.A., Olsen R.J., Long S.W., Snehal R., Davis J.J., Saavedra M.O., et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in houston, Texas. Am J Pathol. 2022 doi: 10.1016/j.ajpath.2022.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2022.01.007</ArticleId><ArticleId IdType="pmc">PMC8812084</ArticleId><ArticleId IdType="pubmed">35123975</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova P., Kemp S.A., Dhar M.S., Papa G., Meng B., Ferreira I., et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599:114&#x2013;119. doi: 10.1038/s41586-021-03944-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03944-y</ArticleId><ArticleId IdType="pmc">PMC8566220</ArticleId><ArticleId IdType="pubmed">34488225</ArticleId></ArticleIdList></Reference><Reference><Citation>Langwig K.E., Gomes M.G.M., Clark M.D., Kwitny M., Yamada S., Wargo A.R., et al. Limited available evidence supports theoretical predictions of reduced vaccine efficacy at higher exposure dose. Sci Rep. 2019;9:3203. doi: 10.1038/s41598-019-39698-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39698-x</ArticleId><ArticleId IdType="pmc">PMC6397254</ArticleId><ArticleId IdType="pubmed">30824732</ArticleId></ArticleIdList></Reference><Reference><Citation>Morens D.M., Taubenberger J.K., Fauci A.S. Universal coronavirus vaccines - an urgent need. N Engl J Med. 2022;386:297&#x2013;299. doi: 10.1056/NEJMp2118468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2118468</ArticleId><ArticleId IdType="pmc">PMC11000439</ArticleId><ArticleId IdType="pubmed">34910863</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockman M.A., Mwimanzi F., Lapointe H.R., Sang Y., Agafitei O., Cheung P., et al. Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults. J Infect Dis. 2021 doi: 10.1093/infdis/jiab592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab592</ArticleId><ArticleId IdType="pmc">PMC8689804</ArticleId><ArticleId IdType="pubmed">34888688</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalamaga M., Christodoulatos G.S., Karampela I., Vallianou N., Apovian C.M. Understanding the Co-epidemic of obesity and COVID-19: current evidence, comparison with previous epidemics, mechanisms, and preventive and therapeutic perspectives. Curr Obes Rep. 2021;10:214&#x2013;243. doi: 10.1007/s13679-021-00436-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13679-021-00436-y</ArticleId><ArticleId IdType="pmc">PMC8080486</ArticleId><ArticleId IdType="pubmed">33909265</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallianou N.G., Evangelopoulos A., Kounatidis D., Stratigou T., Christodoulatos G.S., Karampela I., et al. Diabetes mellitus and SARS-CoV-2 infection: pathophysiologic mechanisms and implications in management. Curr Diabetes Rev. 2021;17 doi: 10.2174/1573399817666210101110253.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573399817666210101110253</ArticleId><ArticleId IdType="pubmed">33388022</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampelas M., Dalamaga M., Karampela I. Does COVID-19 involve the retina? Ophthalmol Ther. 2020;9:693&#x2013;695. doi: 10.1007/s40123-020-00299-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40123-020-00299-x</ArticleId><ArticleId IdType="pmc">PMC7503051</ArticleId><ArticleId IdType="pubmed">32955690</ArticleId></ArticleIdList></Reference><Reference><Citation>Belanger M.J., Hill M.A., Angelidi A.M., Dalamaga M., Sowers J.R., Mantzoros C.S. Covid-19 and disparities in nutrition and obesity. N Engl J Med. 2020;383:e69. doi: 10.1056/NEJMp2021264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2021264</ArticleId><ArticleId IdType="pubmed">32668105</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung D.J., Shah G.L., Devlin S.M., Ramanathan L.V., Doddi S., Pessin M.S., et al. Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies. Blood Canc Discov. 2021;2:568&#x2013;576. doi: 10.1158/2643-3230.bcd-21-0139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2643-3230.bcd-21-0139</ArticleId><ArticleId IdType="pmc">PMC8580617</ArticleId><ArticleId IdType="pubmed">34778797</ArticleId></ArticleIdList></Reference><Reference><Citation>Peeters M., Verbruggen L., Teuwen L., Vanhoutte G., Vande Kerckhove S., Peeters B., et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO open. 2021;6:100274. doi: 10.1016/j.esmoop.2021.100274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.esmoop.2021.100274</ArticleId><ArticleId IdType="pmc">PMC8423808</ArticleId><ArticleId IdType="pubmed">34597941</ArticleId></ArticleIdList></Reference><Reference><Citation>Kow C.S., Hasan S.S. Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. Inflammopharmacology. 2021;29:1075&#x2013;1090. doi: 10.1007/s10787-021-00839-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-021-00839-2</ArticleId><ArticleId IdType="pmc">PMC8266992</ArticleId><ArticleId IdType="pubmed">34241782</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E.G., Lustig Y., Cohen C., Fluss R., Indenbaum V., Amit S., et al. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med. 2021;385:e84. doi: 10.1056/NEJMoa2114583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrotri M., Navaratnam A.M.D., Nguyen V., Byrne T., Geismar C., Fragaszy E., et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021;398:385&#x2013;387. doi: 10.1016/s0140-6736(21)01642-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)01642-1</ArticleId><ArticleId IdType="pmc">PMC8285117</ArticleId><ArticleId IdType="pubmed">34274038</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D.S., Cromer D., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205&#x2013;1211. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y., Mandel M., Bar-On Y.M., Bodenheimer O., Freedman L., Haas E.J., et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385:e85. doi: 10.1056/NEJMoa2114228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114228</ArticleId><ArticleId IdType="pmc">PMC8609604</ArticleId><ArticleId IdType="pubmed">34706170</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad L.J., Chemaitelly H., Bertollini R. Effectiveness of mRNA-1273 and BNT162b2 vaccines in Qatar. N Engl J Med. 2022;386:799&#x2013;800. doi: 10.1056/NEJMc2117933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2117933</ArticleId><ArticleId IdType="pmc">PMC8796790</ArticleId><ArticleId IdType="pubmed">35045222</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S.Y., Slezak J.M., Fischer H., Hong V., Ackerson B.K., Ranasinghe O.N., et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407&#x2013;1416. doi: 10.1016/s0140-6736(21)02183-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)02183-8</ArticleId><ArticleId IdType="pmc">PMC8489881</ArticleId><ArticleId IdType="pubmed">34619098</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D.Y., Gu Y., Wheeler B., Young H., Holloway S., Sunny S.K., et al. Effectiveness of covid-19 vaccines over a 9-month period in North Carolina. N Engl J Med. 2022 doi: 10.1056/NEJMoa2117128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2117128</ArticleId><ArticleId IdType="pmc">PMC8781317</ArticleId><ArticleId IdType="pubmed">35020982</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency . UK Health Security Agency; 2022. SARS-CoV-2 variants of concern and variants under investigation in England: technical briefing 36.https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1056487/Technical-Briefing-36-22.02.22.pdf</Citation></Reference><Reference><Citation>Ferdinands J.M., Rao S., Dixon B.E., Mitchell P.K., DeSilva M.B., Irving S.A., et al. 2022. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19&#x2013;associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance&#x2014;VISION Network, 10 states. August 2021&#x2013;January 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7107e2</ArticleId><ArticleId IdType="pmc">PMC8853475</ArticleId><ArticleId IdType="pubmed">35176007</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Zhao X., Song J., Wu J., Zhu Y., Li M., et al. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerg Microb Infect. 2022;11:477&#x2013;481. doi: 10.1080/22221751.2022.2030200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2030200</ArticleId><ArticleId IdType="pmc">PMC8820826</ArticleId><ArticleId IdType="pubmed">35034583</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo F., Abolhassani H., Du L., Piralla A., Bertoglio F., de Campos-Mata L., et al. Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant. medRxiv. 2022 doi: 10.1101/2022.01.04.22268755. 2022.01.04.22268755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.04.22268755</ArticleId><ArticleId IdType="pmc">PMC9106736</ArticleId><ArticleId IdType="pubmed">35562366</ArticleId></ArticleIdList></Reference><Reference><Citation>Servellita V., Syed A.M., Brazer N., Saldhi P., Garcia-Knight M., Sreekumar B., et al. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. medRxiv. 2022 doi: 10.1101/2022.01.25.22269794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.25.22269794</ArticleId><ArticleId IdType="pmc">PMC8930394</ArticleId><ArticleId IdType="pubmed">35429436</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kr&#xfc;ger N., Schulz S., Cossmann A., Rocha C., Kempf A., et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185:447&#x2013;456. doi: 10.1016/j.cell.2021.12.032. e11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.032</ArticleId><ArticleId IdType="pmc">PMC8702401</ArticleId><ArticleId IdType="pubmed">35026151</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruell H., Vanshylla K., Tober-Lau P., Hillus D., Schommers P., Lehmann C., et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat Med. 2022:1&#x2013;4. doi: 10.1038/s41591-021-01676-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01676-0</ArticleId><ArticleId IdType="pmc">PMC8767537</ArticleId><ArticleId IdType="pubmed">35046572</ArticleId></ArticleIdList></Reference><Reference><Citation>Andeweg S.P., de Gier B., Eggink D., van den Ende C., van Maarseveen N., Ali L., et al. Protection of COVID-19 vaccination and previous infection against omicron BA.1 and Delta SARS-CoV-2 infections, The Netherlands, 22 november 2021- 19 January 2022. medRxiv. 2022 doi: 10.1101/2022.02.06.22270457. 2022.02.06.22270457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.06.22270457</ArticleId><ArticleId IdType="pmc">PMC9373894</ArticleId><ArticleId IdType="pubmed">35961956</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerman B.A., Gerlovin H., Madenci A.L., Kurgansky K.E., Ferolito B.R., Figueroa Mu&#xf1;iz M.J., et al. Comparative effectiveness of BNT162b2 and mRNA-1273 vaccines in U.S. Veterans. N Engl J Med. 2022;386:105&#x2013;115. doi: 10.1056/NEJMoa2115463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2115463</ArticleId><ArticleId IdType="pmc">PMC8693691</ArticleId><ArticleId IdType="pubmed">34942066</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagne M., Moliva J.I., Foulds K.E., Andrew S.F., Flynn B.J., Werner A.P., et al. 2022. mRNA-1273 or mRNA-Omicron Boost in Vaccinated Macaques Elicits Comparable B Cell Expansion, Neutralizing Antibodies and Protection against Omicron. bioRxiv : the preprint server for biology. 2022.02.03.479037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.03.479037</ArticleId><ArticleId IdType="pmc">PMC8947944</ArticleId><ArticleId IdType="pubmed">35447072</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan S.G., Tchetgen Tchetgen E.J., Cowling B.J. Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness. Am J Epidemiol. 2016;184:345&#x2013;353. doi: 10.1093/aje/kww064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kww064</ArticleId><ArticleId IdType="pmc">PMC5013887</ArticleId><ArticleId IdType="pubmed">27587721</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean N.E., Hogan J.W., Schnitzer M.E. Covid-19 vaccine effectiveness and the test-negative design. N Engl J Med. 2021;385:1431&#x2013;1433. doi: 10.1056/NEJMe2113151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe2113151</ArticleId><ArticleId IdType="pmc">PMC8451180</ArticleId><ArticleId IdType="pubmed">34496195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentley E.M., Mather S.T., Temperton N.J. The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination. Vaccine. 2015;33:2955&#x2013;2962. doi: 10.1016/j.vaccine.2015.04.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.04.071</ArticleId><ArticleId IdType="pmc">PMC7127415</ArticleId><ArticleId IdType="pubmed">25936665</ArticleId></ArticleIdList></Reference><Reference><Citation>Openshaw P.J.M. Using correlates to accelerate vaccinology. Science. 2022;375:22&#x2013;23. doi: 10.1126/science.abn0007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn0007</ArticleId><ArticleId IdType="pubmed">34990231</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallajosyula V., Ganjavi C., Chakraborty S., McSween A.M., Pavlovitch-Bedzyk A.J., Wilhelmy J., et al. CD8(+) T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients. Science Immunol. 2021;6 doi: 10.1126/sciimmunol.abg5669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg5669</ArticleId><ArticleId IdType="pmc">PMC8975171</ArticleId><ArticleId IdType="pubmed">34210785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718&#x2013;724. doi: 10.1126/science.abc6027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6027</ArticleId><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y., Mentzer A.J., Liu G., Yao X., Yin Z., Dong D., et al. Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 2020;21:1336&#x2013;1345. doi: 10.1038/s41590-020-0782-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0782-6</ArticleId><ArticleId IdType="pmc">PMC7611020</ArticleId><ArticleId IdType="pubmed">32887977</ArticleId></ArticleIdList></Reference><Reference><Citation>Farber D.L. Tissues, not blood, are where immune cells function. Nature. 2021;593:506&#x2013;509. doi: 10.1038/d41586-021-01396-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-01396-y</ArticleId><ArticleId IdType="pubmed">34035530</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbasi J. The flawed science of antibody testing for SARS-COV-2 immunity. JAMA. 2021;326:1781&#x2013;1782. doi: 10.1001/jama.2021.18919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.18919</ArticleId><ArticleId IdType="pubmed">34673883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kislaya I., Rodrigues E.F., Borges V., Gomes J.P., Sousa C., Almeida J.P., et al. Comparative effectiveness of coronavirus vaccine in preventing breakthrough infections among vaccinated persons infected with Delta and Alpha variants. Emerg Infect Dis. 2022;28:331&#x2013;337. doi: 10.3201/eid2802.211789.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2802.211789</ArticleId><ArticleId IdType="pmc">PMC8798697</ArticleId><ArticleId IdType="pubmed">34876242</ArticleId></ArticleIdList></Reference><Reference><Citation>Viana R., Moyo S., Amoako D.G., Tegally H., Scheepers C., Althaus C.L., et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022 doi: 10.1038/s41586-022-04411-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04411-y</ArticleId><ArticleId IdType="pmc">PMC8942855</ArticleId><ArticleId IdType="pubmed">35042229</ArticleId></ArticleIdList></Reference><Reference><Citation>Riediker M., Briceno-Ayala L., Ichihara G., Albani D., Poffet D., Tsai D.H., et al. Higher viral load and infectivity increase risk of aerosol transmission for Delta and Omicron variants of SARS-CoV-2. Swiss Med Wkly. 2022;152:w30133. doi: 10.4414/smw.2022.w30133.</Citation><ArticleIdList><ArticleId IdType="doi">10.4414/smw.2022.w30133</ArticleId><ArticleId IdType="pubmed">35019196</ArticleId></ArticleIdList></Reference><Reference><Citation>Hay J.A., Kissler S.M., Fauver J.R., Mack C., Tai C.G., Samant R.M., et al. Viral dynamics and duration of PCR positivity of the SARS-CoV-2 Omicron variant. medRxiv. 2022 doi: 10.1101/2022.01.13.22269257. 2022.01.13.22269257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.13.22269257</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhach O., Adea K., Hulo N., Sattonnet P., Genecand C., Iten A., et al. Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron. medRxiv. 2022 doi: 10.1101/2022.01.10.22269010. 2022.01.10.22269010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.10.22269010</ArticleId><ArticleId IdType="pubmed">35395151</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine-Tiefenbrun M., Yelin I., Katz R., Herzel E., Golan Z., Schreiber L., et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021;27:790&#x2013;792. doi: 10.1038/s41591-021-01316-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01316-7</ArticleId><ArticleId IdType="pubmed">33782619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke R., Martinez P.P., Smith R.L., Gibson L.L., Achenbach C.J., McFall S., et al. Longitudinal analysis of SARS-CoV-2 vaccine breakthrough infections reveal limited infectious virus shedding and restricted tissue distribution. medRxiv. 2021 doi: 10.1101/2021.08.30.21262701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.08.30.21262701</ArticleId><ArticleId IdType="pmc">PMC9047214</ArticleId><ArticleId IdType="pubmed">35791353</ArticleId></ArticleIdList></Reference><Reference><Citation>Layan M., Gilboa M., Gonen T., Goldenfeld M., Meltzer L., Andronico A., et al. Impact of BNT162b2 vaccination and isolation on SARS-CoV-2 transmission in Israeli households: an observational study. medRxiv. 2021 doi: 10.1101/2021.07.12.21260377. 2021.07.12.21260377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.07.12.21260377</ArticleId><ArticleId IdType="pmc">PMC8903452</ArticleId><ArticleId IdType="pubmed">35238329</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallapaty S. COVID-19: how Omicron overtook Delta in three charts.10.1038/d41586-022-00632-3, https://www.nature.com/articles/d41586-022-00632-3 Date Accessed:04/03/2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-00632-3</ArticleId><ArticleId IdType="pubmed">35246640</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen H., Tessier E., Turner C., Anderson C., Blomquist P., Simons D., et al. 2022. Comparative Transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants and the Impact of Vaccination: National Cohort Study, England. medRxiv. 2022.02.15.22271001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.15.22271001</ArticleId><ArticleId IdType="pmc">PMC10125873</ArticleId><ArticleId IdType="pubmed">36938806</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N., Dagan N., Cohen C., Hern&#xe1;n M.A., Lipsitch M., Kohane I.S., et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398:2093&#x2013;2100. doi: 10.1016/s0140-6736(21)02249-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)02249-2</ArticleId><ArticleId IdType="pmc">PMC8555967</ArticleId><ArticleId IdType="pubmed">34756184</ArticleId></ArticleIdList></Reference><Reference><Citation>Regev-Yochay G., Gonen T., Gilboa M., Mandelboim M., Indenbaum V., Amit S., et al. 2022. 4th dose COVID mRNA vaccines' immunogenicity &amp; efficacy against omicron VOC. medRxiv. 2022.02.15.22270948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.15.22270948</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: vaccinated people are less likely to get long covid, review finds. BMJ. 2022;376:o407. doi: 10.1136/bmj.o407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o407</ArticleId><ArticleId IdType="pubmed">35172970</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambrano L.D., Newhams M.M., Olson S.M., Halasa N.B., Price A.M., Boom J.A., et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against Multisystem inflammatory syndrome in children among persons aged 12-18 Years - United States, July-december 2021. MMWR (Morb Mortal Wkly Rep) 2022;71:52&#x2013;58. doi: 10.15585/mmwr.mm7102e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7102e1</ArticleId><ArticleId IdType="pmc">PMC8757620</ArticleId><ArticleId IdType="pubmed">35025852</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao T., Israelow B., Suberi A., Zhou L., Reschke M., Pe&#xf1;a-Hern&#xe1;ndez M.A., et al. 2022. Unadjuvanted Intranasal Spike Vaccine Booster Elicits Robust Protective Mucosal Immunity against Sarbecoviruses. bioRxiv : the preprint server for biology. 2022.01.24.477597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.24.477597</ArticleId><ArticleId IdType="pmc">PMC9798903</ArticleId><ArticleId IdType="pubmed">36302057</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalali N., Brustad H.K., Frigessi A., MacDonald E., Meijerink H., Feruglio S., et al. Increased household transmission and immune escape of the SARS-CoV-2 Omicron variant compared to the Delta variant: evidence from Norwegian contact tracing and vaccination data. medRxiv. 2022 doi: 10.1101/2022.02.07.22270437. 2022.02.07.22270437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.07.22270437</ArticleId><ArticleId IdType="pmc">PMC9520116</ArticleId><ArticleId IdType="pubmed">36175424</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng H.F., Ackerson B.K., Luo Y., Sy L.S., Talarico C.A., Tian Y., et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and Delta variants. Nat Med. 2022 doi: 10.1038/s41591-022-01753-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01753-y</ArticleId><ArticleId IdType="pmc">PMC9117141</ArticleId><ArticleId IdType="pubmed">35189624</ArticleId></ArticleIdList></Reference><Reference><Citation>Monge S, Rojas-Benedicto A, Olmedo C, Mazagatos C, Sierra MJ, Limia A, et al. The effectiveness of mRNA vaccine boosters for laboratory-confirmed COVID-19 during a period of predominance of the omicron variant of SARS-CoV-2. Available at SSRN 4035396.</Citation></Reference><Reference><Citation>Abu-Raddad L.J., Chemaitelly H., Ayoub H.H., AlMukdad S., Tang P., Hasan M.R., et al. Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar. medRxiv. 2022 doi: 10.1101/2022.01.18.22269452. 2022.01.18.22269452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.18.22269452</ArticleId><ArticleId IdType="pmc">PMC8929389</ArticleId><ArticleId IdType="pubmed">35263534</ArticleId></ArticleIdList></Reference><Reference><Citation>Accorsi E.K., Britton A., Fleming-Dutra K.E., Smith Z.R., Shang N., Derado G., et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and Delta variants. JAMA. 2022;327:639&#x2013;651. doi: 10.1001/jama.2022.0470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.0470</ArticleId><ArticleId IdType="pmc">PMC8848203</ArticleId><ArticleId IdType="pubmed">35060999</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson M.G., Natarajan K., Irving S.A., Rowley E.A., Griggs E.P., Gaglani M., et al. 2022. Effectiveness of a third dose of mRNA vaccines against COVID-19&#x2013;associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance&#x2014;VISION Network, 10 States. August 2021&#x2013;January 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7104e3</ArticleId><ArticleId IdType="pmc">PMC9351525</ArticleId><ArticleId IdType="pubmed">35085224</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency COVID-19 vaccine surveillance report week 4 UK health security agency. 2022. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050721/Vaccine-surveillance-report-week-4.pdf</Citation></Reference><Reference><Citation>Karampela I., Dalamaga M. Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch Med Res. 2020;51:741&#x2013;742. doi: 10.1016/j.arcmed.2020.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2020.06.004</ArticleId><ArticleId IdType="pmc">PMC7275144</ArticleId><ArticleId IdType="pubmed">32546446</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsilingiris D., Dalamaga M., Liu J. SARS-CoV-2 adipose tissue infection and hyperglycemia: a further step towards the understanding of severe COVID-19. Metabol Open. 2022;13:100163. doi: 10.1016/j.metop.2022.100163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2022.100163</ArticleId><ArticleId IdType="pmc">PMC8755555</ArticleId><ArticleId IdType="pubmed">35039801</ArticleId></ArticleIdList></Reference><Reference><Citation>Syriga M., Karampela I., Dalamaga M., Karampelas M. The effect of COVID-19 pandemic on the attendance and clinical outcomes of patients with ophthalmic disease: a mini-review. Metabol Open. 2021;12:100131. doi: 10.1016/j.metop.2021.100131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metop.2021.100131</ArticleId><ArticleId IdType="pmc">PMC8474871</ArticleId><ArticleId IdType="pubmed">34604730</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann D.M., Boyton R.J. COVID-19 vaccination: the road ahead. Science. 2022;375(6585):1127&#x2013;1132. doi: 10.1126/science.abn1755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn1755</ArticleId><ArticleId IdType="pubmed">35271316</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards A.M., Baric R.S., Saphire E.O., Ulmer J.B. Stopping pandemics before they start: lessons learned from SARS-CoV-2. Science. 2022;375(6585):1133&#x2013;1139. doi: 10.1126/science.abn1900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn1900</ArticleId><ArticleId IdType="pubmed">35271333</ArticleId></ArticleIdList></Reference><Reference><Citation>Koelle K., Martin M.A., Antia R., Lopman B., Dean N.E. The changing epidemiology of SARS-CoV-2. Science. 2022;375(6585):1116&#x2013;1121. doi: 10.1126/science.abm4915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm4915</ArticleId><ArticleId IdType="pmc">PMC9009722</ArticleId><ArticleId IdType="pubmed">35271324</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>